Keros Therapeutics Reports Q2 Loss, Secures $20M Takeda Milestone, CFO Transition Confirmed
KROS is trading near its 52-week low of $9.69 (3.4% above the low).
Summary
Keros Therapeutics reported a Q2 net loss but secured a $20 million Takeda milestone, extending its cash runway into mid-2028. However, the company lost access to its ATM financing program, and its CFO resigned.
Key Events · Earnings and Guidance · KROS
-
Q2 Financial Results
The company reported a net loss of $28.7 million for Q2 2026 and $52.4 million for the six months ended June 30, 2026. Operating cash flow was negative $23.95 million for the six-month period.
-
Takeda Milestone Payment
A $20.0 million development milestone payment from Takeda was achieved in July 2026, triggered by the dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial. Keros expects to distribute 25% of the net cash proceeds to stockholders.
-
Cash Runway Update
Existing cash and cash equivalents of $257.6 million as of June 30, 2026, are projected to fund operations into the first half of 2028.
-
ATM Program Ineligibility
As of June 30, 2026, the company is no longer eligible to offer and sell shares under its At-The-Market (ATM) program, limiting future capital raising options.
Analysis · KROS · Life Sciences
Keros Therapeutics reported a net loss of $28.7 million for Q2 2026 and $52.4 million for the first six months of 2026, with negative operating cash flow of $23.95 million for the six-month period. However, the company announced a significant $20.0 million development milestone payment from Takeda in July 2026, with 25% of net cash proceeds expected to be distributed to stockholders. The company projects its existing cash and cash equivalents of $257.6 million will fund operations into the first half of 2028. A notable concern is the company's ineligibility to use its At-The-Market (ATM) program for future share sales, limiting financing flexibility. Additionally, the CFO, Keith Regnante, resigned effective August 3, 2026, with Annita Tanini appointed as interim Principal Financial Officer.
At the time of this filing, KROS was trading at $10.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $200.1M. The 52-week trading range was $9.69 to $22.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.